Answers are grounded in this paper and cite their sources.
Lutetium ( 177 Lu) oxodotreotide is the very first registered PRRT to be brought to the European NET patient community, providing an alternative option by targeting tumors with radiolabeled molecules that bind to specific receptors expressed by the tumor."
No takes yet. Share an insight, caveat, or question.
Martyn Caplin (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: